<DOC>
	<DOCNO>NCT02456844</DOCNO>
	<brief_summary>To study Pharmacokinetics ( PK ) parameter montelukast , flurbiprofen , midazolam , digoxin , pravastatin , MTX coadministered BMS-986142 .</brief_summary>
	<brief_title>Study Investigate Effect BMS-986142 Pharmacokinetics ( PK ) Methotrexate Probe Substrate Cocktail Healthy Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Flurbiprofen</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Groups 1 2 : 1 . Written inform consent subject . 2 . Body mass index ( BMI ) 18.0 32.0 kg/m2 , inclusive 3 . Nonsmokers . 4 . Normal renal function screen evidence estimate glomerular filtration rate ( GFR ) &gt; 90 mL/min/1.73 m2 . 5 . Subject reenrollment . 6 . Males sexually active woman childbearing potential ( WOCBP ) must agree follow instruction method ( ) contraception duration treatment study drug plus 5 halflives BMS986142 . 7 . Male subject must willing refrain sperm donation entire study plus 5 halflives BMS986142 . Group 1 : 1 . Healthy male female ( childbearing potential ) subject determine medical history , clinical assessment . 2 . Women must document proof childbearing potential must breast feeding . Group 2 : 1 . Healthy male subject determine medical history , clinical assessment . 1 . Administration live vaccine include polio vaccine course study , 12 week prior first dose study drug , 30 day last dose study drug . 2 . Active tuberculosis ( TB ) require treatment within previous 3 year . 3 . History herpes zoster . 4 . Subjects experience recent infection , upper respiratory infection , .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>